Skip to content

Effect of sugammadex sodium on pulmonary complications after pulmonary lobectomy in patients with pulmonary hypofunction

Effect of sugammadex sodium on pulmonary complications after pulmonary lobectomy in patients with pulmonary hypofunction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056585
Enrollment
Unknown
Registered
2022-02-08
Start date
2022-02-08
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pulmonary complications

Interventions

Sponsors

Beijing Chest Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged> 18 years, no gender limit, ASA I- III; 2. Patients undergoing elective lobectomy; 3. Clear consciousness and good communication with patients; 4. The predicted FEV1 %=50-70% and/or MVV% < 75% in moderate and moderate to severe pulmonary function decline.

Exclusion criteria

Exclusion criteria: 1. Patients with myasthenia gravis; 2. Liver and kidney dysfunction, urinary calculi; 3. BMI > 30; 4. Severe cardiovascular and cerebrovascular diseases and diabetes mellitus; 5. Patients who have undergone pneumonectomy before; 6. Patients who were converted to thoracotomy or had serious surgical complications requiring a second operation; 7. Patients converted to complete pneumonectomy during operation; 8. Patients with neostigmine contraindications.

Design outcomes

Primary

MeasureTime frame
Postoperative pulmonary complications;

Secondary

MeasureTime frame
Time from TOF=2 to TOFr=0.9;Time from dosing to extubation;C reactive protein;Procalcitonin (PCT);Pain score;Nausea and vomiting;

Countries

China

Contacts

Public ContactLiu Wei
lw1200@sina.com+86 15111099572

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026